Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells

Angiogenesis

Volumn 16, Issue 2, 2013, Pages 373-386

  Pasquier, Eddy ^a,b   Tuset, Maria Pia ^a   Street, Janine ^a   Sinnappan, Snega ^a,f   MacKenzie, Karen L ^a   Braguer, Diane ^c   Andre, Nicolas ^b,c,d   Kavallaris, Maria ^a,e  

^a University of New South Wales   (Australia)

^b Metronomics Global Health Initiative   (France)

^c University of the Mediterranean Aix Marseille II   (France)

^d TIMONE HOSPITAL   (France)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

III tubulin; ABC transporters; Angiogenesis; Cancer; Metronomic chemotherapy; Vascular endothelial cells

Indexed keywords

ABC TRANSPORTER; BETA 2 TUBULIN; BETA TUBULIN; BETA3 TUBULIN; ETOPOSIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VASCULAR ENDOTHELIUM;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; GENE SILENCING; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUBULIN;

EID: 84877872854     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9321-x     Document Type: Article

References (45)

1. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7):1878-1886 (Pubitemid 30207647)
2. Kerbel RS, Viloria-Petit A, Klement G, Rak J (2000) 'Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 36(10):1248-1257 (Pubitemid 30407012)
3. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19(4):1195-1206 (Pubitemid 32176298)
4. Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6):423-436 (Pubitemid 38745528)
5. Pasquier E, Kavallaris M, Andre N (2010) Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 7(8):455-465
6. Andre N, Padovani L, Pasquier E (2011) Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy? Future Oncol 7(3):385-394
7. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15-R24
8. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30):4899-4905
9. Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI (2009) Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 28(5):723-730
10. Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, Dieckmann K, Schmook MT, Haberler C, Leiss U, Slavc I (2011) Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 59(3):511-517
11. Kerbel RS (1991) Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays 13(1):31-36 (Pubitemid 21892580)
12. Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404-407 (Pubitemid 28027321)
13. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I (2004) Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 351(3):250-259 (Pubitemid 38916042)
14. Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, Klagsbrun M (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64(22):8249-8255 (Pubitemid 39491762)
15. Rigolin GM, Fraulini C, Ciccone M, Mauro E, Bugli AM, De Angeli C, Negrini M, Cuneo A, Castoldi G (2006) Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood 107(6):2531-2535 (Pubitemid 43345578)
16. Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15(15):4838-4846
17. Virrey JJ, Golden EB, Sivakumar W, Wang W, Pen L, Schonthal AH, Hofman FM, Chen TC (2009) Glioma-associated endothelial cells are chemoresistant to temozolomide. J Neurooncol 95(1):13-22
18. Akiyama K, Ohga N, Hida Y, Kawamoto T, Sadamoto Y, Ishikawa S, Maishi N, Akino T, Kondoh M, Matsuda A, Inoue N, Shindoh M, Hida K (2012) Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment. Am J Pathol 180(3):1283-1293
19. De Souza R, Zahedi P, Badame RM, Allen C, Piquette-Miller M (2011) Chemotherapy dosing schedule influences drug resistance development in ovarian cancer. Mol Cancer Ther 10(7):1289-1299
20. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS (2011) Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia 13(1):40-48
21. MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S, Moore MA (2002) Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras. Oncogene 21(27):4200-4211 (Pubitemid 34753826)
22. Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, Lawley TJ (1992) HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 99(6):683-690 (Pubitemid 23002027)
23. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M (2010) ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther 9(5):1408-1418
24. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, Flemming CL, Smith J, Fletcher JI, Gherardi S, Kwek CK, Russell AJ, Valli E, London WB, Buxton AB, Ashton LJ, Sartorelli AC, Cohn SL, Schwab M, Marshall GM, Perini G, Norris MD (2011) ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 103(16):1236-1251
25. McCarroll JA, Gan PP, Liu M, Kavallaris M (2010) BetaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 70(12):4995-5003
26. Winer J, Jung CK, Shackel I, Williams PM (1999) Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270(1):41-49 (Pubitemid 29230718)
27. Haber M, Norris MD, Kavallaris M, Bell DR, Davey RA, White L, Stewart BW (1989) Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res 49(19):5281-5287 (Pubitemid 19240461)
28. Gan PP, Pasquier E, Kavallaris M (2007) Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67(19):9356-9363 (Pubitemid 47535925)
29. Gan PP, Kavallaris M (2008) Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity. Cancer Res 68(23):9817-9824
30. Pourroy B, Honore S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, Braguer D (2006) Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res 66(6):3256-3263
31. Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M (2006) Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J Natl Cancer Inst 98(19):1363-1374 (Pubitemid 44538158)
32. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J Jr (2009) Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res 69(2):416-421
33. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10(3):194-204
34. Pasquier E, Honore S, Braguer D (2006) Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist Update 9(1-2):74-86 (Pubitemid 43928807)
35. Baguley BC (2010) Multiple drug resistance mechanisms in cancer. Mol Biotechnol 46(3):308-316
36. Merchan JR, Jayaram DR, Supko JG, He X, Bubley GJ, Sukhatme VP (2005) Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 113(3):490-498 (Pubitemid 40038720)
37. Pasquier E, Andre N, Braguer D (2007) Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets 7(6):566-581 (Pubitemid 47358143)
38. Vassileva V, Allen CJ, Piquette-Miller M (2008) Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol Cancer Ther 7(3):630-637 (Pubitemid 351482145)
39. De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, Piquette-Miller M (2010) Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol Cancer Ther 9(6):1820-1830
40. Verdier-Pinard P, Pasquier E, Xiao H, Burd B, Villard C, Lafitte D, Miller LM, Angeletti RH, Horwitz SB, Braguer D (2009) Tubulin proteomics: towards breaking the code. Anal Biochem 384(2):197-206
41. Gan PP, McCarroll JA, Byrne FL, Garner J, Kavallaris M (2011) Specific beta-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells. PLoS ONE 6(6):e21717
42. Stapor PC, Murfee WL (2011) Identification of class III beta-tubulin as a marker of angiogenic perivascular cells. Microvasc Res 83(2):257-262
43. Seve P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9(2):168-175 (Pubitemid 351150128)
44. Vilmar AC, Santoni-Rugiu E, Sorensen JB (2011) Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin Cancer Res 17(15):5205-5214
45. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW (2012) Association between class III beta-tubulin expression and response to paclitaxel/ vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77(1):9-15